MRIAN‐Dox treatment enhanced PKM2 activity (Figure 6o), glucose uptake (Figure 6p), pyruvate level (Figure 6q), lactate level (Figure 6r), LDH activity (Figure 6s), ATP production (Figure 6t), and mitochondrial potential (Figure 6u) in T‐ALL cells compared to Dox treatment. This evidence concerns the gene PKM and acute lymphoblastic leukemia.